Energetic ingredient in green tea displays promise in leukemia trials Mayo Clinic experts are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate , a dynamic component in green tea Click to see more . The trial established that patients with chronic lymphocytic leukemia can tolerate the chemical fairly well when high doses are administered in capsule form and that lymphocyte count was reduced in one-third of individuals. Today online in the Journal of Clinical Oncology The results appear. ‘We found not just that patients tolerated the teas at very high doses, but that lots of of them saw regression to some extent of their persistent lymphocytic leukemia,’ says Tait Shanafelt, M.D., Mayo Clinic hematologist and lead author of the study.
The research team discovered that inhibition of astrocyte activation blunted the activation of microglia , reduced toxic amyloid levels, improved synaptic function and plasticity, and preserved cognitive function. Norris and collaborators suggest that similar astrocyte-based methods could be developed to treat humans suffering from Alzheimer's disease, or additional neurodegenerative diseases possibly. This study provides proof theory that therapeutically targeting astrocytes could be beneficial. Norris has been named the main investigator on a fresh NIH award totaling $1,498,423 over a period of 5 years, to keep this line of research on Alzheimer's disease..